"Palleon Pharmaceuticals reports Phase I/II trial results of E-602 for solid tumours" was originally created and published by ...

East Windsor is excited to welcome another pharmaceutical company Rising Pharmaceuticals to join the many other high-tech ...

Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) on November 5 and set a ...

From drug pricing to reforming the drug regulatory process, Trump’s re-election has plenty of implications for the pharma ...

Acadia Pharmaceuticals sold its priority review voucher for $150 million. Haleon named Vistar Media, a location-based ad ...

Palvella Therapeutics announced the first patient has been dosed in SELVA, a multicenter, Phase 3 clinical trial designed to evaluate the ...

AbbVie has entered into a partnership and option-to-license agreement with EvolveImmune Therapeutics, to develop ...

The 6th RNAi-Based Therapeutics Summit is returning to Boston in January 2025 with fresh insights and perspectives.

With the formation of a new strategic partnership, Dyno Therapeutics is responsible for the development of novel AAV capsids.

NEWTON, Mass. (AP) — NEWTON, Mass. (AP) — Karyopharm Therapeutics Inc. (KPTI) on Tuesday reported a loss of $32.1 million in its third quarter. The Newton, Massachusetts-based company said it had a ...